HROW Harrow Health Inc.

Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021

Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021

NASHVILLE, Tenn., July 26, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the second quarter and six months ended June 30, 2021, on Tuesday, August 10, 2021, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update.

Conference Call Details: 
Date:Tuesday, August 10, 2021
Time:4:45 p.m. Eastern time
Participant Dial-in:1-833-953-2434 (U.S.)

1-412-317-5763 (International)
Replay Dial-in (Passcode 10157937):

(telephonic replay through August 17, 2021)
1-877-344-7529 (U.S.)

1-412-317-0088 (International)
Webcast: (online replay through November 10, 2021)harrowinc.com

About Harrow Health

Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. Harrow Health also holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com.

Contact:

Jamie Webb, Director of Communications and Investor Relations

[email protected]

615-733-4737

 



EN
26/07/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harrow Health Inc.

 PRESS RELEASE

ImprimisRx Announces Leadership Changes

ImprimisRx Announces Leadership Changes Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced leadership changes at its wholly-owned subsidiary, ImprimisRx. Frank Mullery has been appointed as Chief Executive Officer and Bridseida Cruz has been appointed as Head of Quality of ImprimisRx. Mr. Mullery is a senior executive with over 20 years of leadership ex...

 PRESS RELEASE

Harrow to Acquire Melt Pharmaceuticals

Harrow to Acquire Melt Pharmaceuticals NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. The closing of this acquisition is subject to customary closing conditions, including approval by Melt stockholders, excluding Harrow and ...

 PRESS RELEASE

Harrow Launches Harrow Access for All (HAFA)

Harrow Launches Harrow Access for All (HAFA) HAFA to Expand Harrow’s Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of Harrow Access for All (“HAFA”), expanding Harrow’s commitment to make it easier and more affordable for patients to access Harrow’s full range of branded, generic, and compounded ophthalmic medications. H...

 PRESS RELEASE

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Harrow Announces Agenda and Speakers for Investor & Analyst Day NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor & Analyst Day on Friday, September 26, from 11:30 a.m. ET to 3 p.m. ET in New York. The event will also be webcast live and instructions for accessing the webcast are below. Harrow’s Investor & Analyst Day will include a comprehensive overview of Harrow’s business, featuring presentations from the Company’s leadership t...

 PRESS RELEASE

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due...

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030 Announces Commitment for New $40 Million Revolving Credit Facility Issues Conditional Notice of Redemption of 11.875% Senior Notes due 2027 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has commenced a private offering (the “Offering”) of $250.0 million aggregate principal amount of senior unsecured notes due 2030 (the “2030 Notes”), subject to market and certain other conditi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch